Topline results from the global, multicenter, open-label, Phase II/III OptimUM-02 clinical trial were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, held May 29–June 2. The trial evaluated the safety and efficacy of Ideaya Biosciences’ darovasertib, a first-in-class, selective protein kinase C inhibitor, in combination with Pfizer’s Xalkori (crizotinib), a multiple kinase inhibitor targeting mesenchymal-to-epithelial transition factor (MET), anaplastic lymphoma kinase (ALK), and receptor tyrosine kinase proto-oncogene 1 (ROS1), in first-line treatment of HLA A*02:01-negative metastatic uveal melanoma (UM).
In the OptimUM-02 study, the efficacy population included 313 patients, of whom 210 received darovasertib in combination with xalkori and 103 received investigator's choice. The combination met its primary efficacy objective, improving median progression-free survival, as assessed by independent, blinded central assessment, to 6.9 months compared with 3.1 months with investigator's choice (hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.30–0.59; p
Overall survival data are still incomplete, although an early favorable trend is observed. Treatment-emergent adverse events (TEAEs) occurred in 98.31% of patients receiving darovasertib in combination with xalkori compared with 89.01% of those receiving investigator's choice, while the rates of grade 3 or 4 TEAEs were generally similar: 40.61% vs. 37.01% . Importantly, the rate of serious TEAEs was lower with darovasertib in combination with xalkori than with investigator's choice: 9.21% vs. 25.01% . Treatment discontinuations due to TEAEs were also lower with darovasertib and xalkori: 2.51% and 10.01%, respectively, compared with 19.01% with investigator's choice. These results support the potential for darovasertib in combination with xalkori to serve as a new standard of care if approved for the treatment of HLA A*02:01-negative metastatic uveal melanoma.
The combination of darovasertib and xalkori occupies a differentiated competitive position as there are currently no directly approved or late-stage competitors specifically targeting HLA A*02:01-negative first-line metastatic uveal melanoma. Immunocore's Kimmtrak (tebentafusp) remains the only approved systemic therapy with a proven survival benefit in metastatic uveal melanoma, but its use is limited to HLA A*02:01-positive patients, leaving HLA A*02:01-negative patients untreated.
DelcathSystems' Hepzato (melphalan hydrochloride) is a liver-delivery system for select patients with unresectable liver metastases, making it an additional rather than a direct systemic competitor. The closest competitor in development is Replimune's sturlimogene erparepvec in combination with Bristol Myers Squibb's (BMS) Opdivo (nivolumab), which is currently being tested in the randomized Phase II/III REVEAL trial versus BMS's Yervoy (ipilimumab) in combination with Opdivo in patients with immune checkpoint inhibitor-naive metastatic uveal melanoma, regardless of HLA status.
According to analysts at GlobalData, global sales of darovasertib are expected to reach $709 million by 2032. The planned filing of a drug application for registration in the second half of 2026 could allow Ideaya to carve out a niche in the US market, while Servier's rights outside the US open up broader commercial opportunities in international markets.
Despite the positive results of the OptimUM-02 study, the commercial potential of darovasertib may be limited by the small size of the metastatic uveal melanoma market, meaning that Ideaya will likely need to successfully expand into earlier treatment stages, particularly neoadjuvant primary uveal melanoma, to achieve stronger long-term revenue growth.
The article "ASCO 2026: Darovasertib Raises the Bar in Metastatic Uveal Melanoma" was originally created and published by Clinical Trials Arena, a brand owned by GlobalData.
The information on this website is provided in good faith and is for general informational purposes only. It is not intended to constitute advice on which you should rely, and we make no representations, warranties, or promises, express or implied, regarding its accuracy or completeness. Before making or refraining from making any decisions based on the information provided on our website, you should seek professional or specialized advice.